Search

Your search keyword '"Rubio MJ"' showing total 93 results

Search Constraints

Start Over You searched for: Author "Rubio MJ" Remove constraint Author: "Rubio MJ"
93 results on '"Rubio MJ"'

Search Results

1. Preoperative study of the inner segment/outer segment junction of photoreceptors by spectral-domain optical coherence tomography as a prognostic factor in patients with epiretinal membranes

2. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

3. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models

4. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections

5. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy

6. Preoperative study of the inner segment/outer segment junction of photoreceptors by spectral-domain optical coherence tomography as a prognostic factor in patients with epiretinal membranes

9. Management of advanced ovarian cancer in Spain: an expert Delphi consensus

10. SEOM clinical guidelines for cervical cancer (2019)

11. Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study

12. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.

13. Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).

14. Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

15. Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study.

16. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

17. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).

18. Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus.

19. Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03.

20. Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.

21. Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.

22. The NED foundation experience: A model of global neurosurgery.

23. A randomized, non-inferiority trial on the DuoStim strategy in PGT-A cycles.

24. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.

25. Recreational physical activity reduces breast cancer recurrence in female survivors of breast cancer: A meta-analysis.

26. Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network.

27. Optimism as a protective factor against the psychological impact of COVID-19 pandemic through its effects on perceived stress and infection stress anticipation.

28. Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.

29. [Sepsis Code: dodging mortality in a tertiary hospital].

30. Reply to Elias et al.: Multiproxy evidence of widespread landscape disturbance in multiple Azorean lakes before the Portuguese arrival.

31. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.

32. Climate change facilitated the early colonization of the Azores Archipelago during medieval times.

33. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).

34. Educational level as a protective factor against the influence of depressive symptoms on cognition in older adults: implications for functional independence during a 10-year follow-up.

35. Enhanced N170 to outgroup faces: Perceptual novelty or prejudice?

36. Management of advanced ovarian cancer in Spain: an expert Delphi consensus.

37. SEOM clinical guideline in ovarian cancer (2020).

38. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.

39. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

40. Prejudice drives exogenous attention to outgroups.

41. Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO).

42. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

43. SEOM clinical guidelines for cervical cancer (2019).

44. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.

45. Initial clinical outcomes and prognostic variables in the implementation of a Code Sepsis in a high complexity University Hospital.

46. The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

47. Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma.

48. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.

49. Aptamer Selection against a Trichomonas vaginalis Adhesion Protein for Diagnostic Applications.

50. Involvement of stanniocalcins in the deregulation of glycaemia in obese mice and type 2 diabetic patients.

Catalog

Books, media, physical & digital resources